Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA ...

The abrupt exit of the former CBER director raises questions about the FDA’s leadership. For now, newly appointed CDER head ...

The new direct-to-consumer ad signals J&J’s confidence in its capacity to meet demand for the cell therapy after earlier ...

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

The vaccine maker’s board intends to recommend a pending offer from investment firms Nordic Capital and Permira, which would ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...